Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Decourt

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Expert Opinion on Emerging Drugs|December 15, 2023
Cancer drugs with high repositioning potential for Alzheimer's diseaseJad Majeed, Marwan N Sabbagh, Min H Kang, et al.
Neurology and Therapy|January 19, 2026
Dementia in Progressive Supranuclear Palsy: A Narrative ReviewKathleen S Moore, Yara S Stipho, Nicki Niemann, et al.
Journal of Neuroscience Methods|December 17, 2013
A cellular model of amyloid precursor protein processing and amyloid-β peptide productionMimi P Macias, Amanda M Gonzales, Ashley L Siniard, et al.
Platelets|July 11, 2012
Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept studyBoris Decourt, Aaron Walker, Amanda Gonzales, et al.
Frontiers in Nutrition|January 28, 2026
Linking dietary patterns to Alzheimer's disease biomarkers with network mathematical modeling could enable new approach methodologies in preventative AD research: a narrative interdisciplinary reviewTravis B Thompson, Andrew C Shin, Boris Decourt, et al.
Neuro-Degenerative Diseases|July 9, 2026
Autophagy in Alzheimer's disease: mechanisms, clinical trials, and horizonsTshibambe N Tshimbombu, Kyle E Thurmann, Boris Decourt, et al.
Open Access Journal of Clinical Trials|March 4, 2020
MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's DiseaseBoris Decourt, Jeffrey Wilson, Aaron Ritter, et al.
Current Alzheimer Research|January 27, 2017
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled TrialBoris Decourt, Denise Drumm-Gurnee, Jeffrey Wilson, et al.
Nutrition & Diabetes|January 3, 2026
Relationships between diabetes, vitamin D status, depression, and Hispanic ethnicity: a project FRONTIER studyRiley McCready, Claudia Morris, Philip Antwi-Adjei, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Expert Opinion on Emerging Drugs|December 15, 2023
Cancer drugs with high repositioning potential for Alzheimer's diseaseJad Majeed, Marwan N Sabbagh, Min H Kang, et al.
Neurology and Therapy|January 19, 2026
Dementia in Progressive Supranuclear Palsy: A Narrative ReviewKathleen S Moore, Yara S Stipho, Nicki Niemann, et al.
Journal of Neuroscience Methods|December 17, 2013
A cellular model of amyloid precursor protein processing and amyloid-β peptide productionMimi P Macias, Amanda M Gonzales, Ashley L Siniard, et al.
Platelets|July 11, 2012
Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept studyBoris Decourt, Aaron Walker, Amanda Gonzales, et al.
Frontiers in Nutrition|January 28, 2026
Linking dietary patterns to Alzheimer's disease biomarkers with network mathematical modeling could enable new approach methodologies in preventative AD research: a narrative interdisciplinary reviewTravis B Thompson, Andrew C Shin, Boris Decourt, et al.
Neuro-Degenerative Diseases|July 9, 2026
Autophagy in Alzheimer's disease: mechanisms, clinical trials, and horizonsTshibambe N Tshimbombu, Kyle E Thurmann, Boris Decourt, et al.
Open Access Journal of Clinical Trials|March 4, 2020
MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's DiseaseBoris Decourt, Jeffrey Wilson, Aaron Ritter, et al.
Current Alzheimer Research|January 27, 2017
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled TrialBoris Decourt, Denise Drumm-Gurnee, Jeffrey Wilson, et al.
Nutrition & Diabetes|January 3, 2026
Relationships between diabetes, vitamin D status, depression, and Hispanic ethnicity: a project FRONTIER studyRiley McCready, Claudia Morris, Philip Antwi-Adjei, et al.
Pageof 5